Clinical Trials


Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

The recruitment status of this study is unknown.

Verified November 2001

Gilead Sciences

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: February 9, 2001
Last updated: June 23, 2005
Last Verified: November 2001
History of Changes


The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get worse. This study will allow patients to obtain tenofovir DF before it is approved for marketing.

Condition Intervention
HIV Infections

Drug : Tenofovir disoproxil fumarate

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Study Start Date: February 2001

Detailed Description:

Patients receive daily doses of tenofovir DF.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have a viral load (level of HIV in the blood) of at least 10,000 copies/ml by PCR within the previous 2 months.
  • Have a CD4 count of 100 cells/mm3 or lower within the previous 2 months. Patients with a CD4 count above 100 and as high as 200 cells/mm3 may also be eligible if they had an opportunistic (AIDS-related) infection within the past 90 days.
  • Have failed treatment with at least 2 protease inhibitors (PIs) or at least 1 PI plus a nonnucleoside reverse transcriptase inhibitor (NNRTI).
  • Are not able to get effective treatment with a combination of currently approved anti-HIV drugs.
  • Are at least 18 years old.
  • Have a negative serum pregnancy test.
  • Are willing to use a barrier method of birth control (both males and females) while on the study and for 30 days after taking the drug.

  • Exclusion Criteria
    Patients will not be eligible for this study if they:
  • Have or have had kidney disease or bone disease.
  • Are pregnant or breast-feeding.
  • Abuse alcohol or drugs.
  • Are taking, or have taken within 7 days of enrolling in the study, adefovir dipivoxil or drugs that may cause kidney problems, including aminoglycoside antibiotics, cidofovir, foscarnet, intravenous (IV) amphotericin B, IV pentamidine, IV vancomycin, and chemotherapy (e.g., cisplatin).
  • Have any medical conditions or have had any medications that the study investigator
believes will make him/her unsuitable for the study.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00011089


United States, California
Medical Information
Foster City, California, United States, 94404

Sponsors and Collaborators

Gilead Sciences
More Information

More Information

Responsible Party: Gilead Sciences Identifier: NCT00011089   History of Changes  
Other Study ID Numbers: 283G  
Study First Received: February 9, 2001  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Disease Progression
Reverse Transcriptase Inhibitors
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections
Tenofovir processed this data on July 20, 2018
This information is provided by